Current Securities Class Action Cases

Federman & Sherwood regularly posts press releases about new class action securities cases, which includes the class period and deadlines for appointment of lead plaintiffs. Please review any of the case listings below, and if you bought a security during the class period, we invite you to return an investor certification to our office. Our link to an investor certification for any of the cases can be found below each respective press release on that company. Once completed, please return to our office by email to rkh@federmanlaw.com or fax to (405) 239-2112.

Depomed, Inc. [NASDAQ: DEPO]

Oklahoma City, OK (August 23, 2017) – On August 18, 2017, a securities class action lawsuit was filed in the United States District Court for the Northern District of California against Depomed, Inc. (NASDAQ: DEPO). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is February 26, 2015 through August 7, 2017. More specifically, the Complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Depomed engaged in questionable practices in connection with the sales and marketing of the Company's opioid products; (ii) the foregoing conduct, when it became known, would likely subject the Company to heightened legal and regulatory scrutiny; and (iii) as a result, Depomed's public statements were materially false and misleading at all relevant times.

On August 7, 2017, post-market, Depomed disclosed that the Company recently received a request for information from the ranking minority member of the United States Senate Committee on Homeland Security and Governmental Affairs related to the promotion of opioids and that Depomed had also received subpoenas related to opioid sales and marketing from the Office of the Attorney General of Maryland and the United States Department of Justice.

On this news, Depomed's share price fell $3.09, to close at $6.15 on August 8, 2017.

Plaintiff seeks to recover damages on behalf of all Depomed, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Tuesday, October 17, 2017 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.

To join this class action, click here to obtain an investor certification. Once complete, please email this form to rkh@federmanlaw.com, fax to us at (405) 239-2112 or send by regular mail to Federman & Sherwood, 10205 North Pennsylvania Avenue, Oklahoma City, OK 73120, ATTN: Robin.